(EMAILWIRE.COM, August 31, 2018 ) The global cell line development market is segmented on the basis of products, sources, types of cell lines, applications, and geographies. Based on products, the global market is categorized into equipment and media and reagents. The media and reagents segment is further divided into serum, media, and reagents.

The cell line development market, by type of cell lines is segmented into primary cell lines, continuous cell lines, hybridomas, and recombinant cell lines. On the basis of source, the market is segmented into mammalians, insects, and amphibians. On the basis of applications, the market is segmented into bioproduction, tissue engineering and regenerative medicine, toxicity testing, research, and drug discovery

Factors such as increasing demand for monoclonal antibodies, rising vaccine production, and use of innovative technologies propel the growth of the market. Some of the opportunities for the market are low income countries like India and Africa lacking access to basic healthcare and increasing risk of pandemic and communicable diseases. However, in spite of innovative technologies in the market, developing stable and authentic cell lines remains a major challenge of this market.

Download Free Brochure: https://www.marketsandmarkets.com/pdfdownload.asp?id=152900899

Some of the major players in the global cell line development market include American Type Culture Collection (ATCC) (U.S.), Lonza Group AG (Switzerland), Thermo Fisher Scientific, Inc. (U.S.), GE Healthcare (U.K.), Sigma-Aldrich Corporation (U.S.), Selexis SA (Switzerland), European Collection of Cell Cultures (ECACC) (U.K.), Corning, Inc. (U.S.), WuXi AppTec, Inc. (China), and Sartorious AG (Germany).

Contact:
Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
newsletter@marketsandmarkets.com